Nakanishi (7716) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
1 Nov, 2026Executive summary
FY2023 net sales rose 22.6% YoY to ¥59,692m; EBITDA increased 1.6% to ¥17,775m, while operating income fell 7.1% to ¥14,297m.
Income attributable to owners of parent increased 83.1% to ¥22,836m, including ¥11,498m gain on step acquisitions.
Financial highlights
Ordinary income declined 2.3% YoY to ¥17,238m; diluted EPS was ¥267.29, versus ¥145.11 in FY2022.
Profit before income taxes rose to ¥28,808m from ¥17,297m; comprehensive income increased 80.6% to ¥25,580m.
Operating cash flow was ¥8,549m versus ¥7,764m; cash and cash equivalents ended FY2023 at ¥25,973m, down ¥5,759m.
Outlook and guidance
FY2024 forecast: net sales ¥74,432m (+24.7% YoY), EBITDA ¥17,770m (~0.0%), and operating income ¥12,652m (-11.5%).
FY2024 ordinary income is forecast at ¥13,088m (-24.1%) and net income attributable to owners at ¥8,894m (-61.1%).
Forecast assumes ¥135 per U.S. dollar and ¥150 per euro; annual dividend forecast is ¥52 per share.
Latest events from Nakanishi
- Double-digit profit growth, upward guidance revision, and U.S. acquisitions highlight the quarter.7716
Q2 2026 - Q1 2026 net income soared 803.9% on 21.3% sales growth, with all segments posting strong gains.7716
Q1 2026 - Acquisition boosts U.S. market share and raises FY2026 sales and profit forecasts.7716
Acquisition presentation - Net sales up 5.4% YoY, but DCI impairment led to a net loss; record sales and profit forecast for FY2026.7716
Q4 2025 - Net sales up 3.8% YoY, but EBITDA and net income declined; guidance unchanged.7716
Q3 2025 - Surgical growth offset flat sales, but net income dropped 50% amid currency headwinds.7716
Q2 2025 - Sales surged 37.4% but net profit dropped 63.7%; outlook and dividend steady.7716
Q3 2024 - Sales surged 36.4% year-over-year, but net income declined 11.9% amid mixed segment results.7716
Q2 2024 - Sales rose, but profits plunged on forex and tax hits; outlook lowered amid global risks.7716
Q1 2025